Clinical Trial Update: Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating bevacizumab in combination with cytotoxic chemotherapy for endometrial cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Cytotoxic chemotherapy (various agents)

Snippet

Sponsor: The Cleveland Clinic | Conditions: Endometrial Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-04-26